INVO Fertility Reports Improved Financial Results Amid Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
INVO Fertility's stock surged by 67.74% as it crossed above the 5-day SMA, reflecting strong investor interest.
The company reported a significant reduction in net loss for Q1 2026, down to $5.54 million from $17.40 million in the previous year, primarily due to the discontinuation of NAYA therapeutics. Additionally, revenue grew by 23% to $2.01 million, driven by strategic initiatives and the acquisition of Family Beginnings, which added a fourth clinic. This positive financial outlook has bolstered investor confidence, leading to a notable increase in stock price.
The improved financial performance and strategic acquisitions position INVO Fertility for potential future profitability, attracting investor attention in a recovering market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IVF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IVF
About IVF
INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shuttle Pharmaceuticals Subsidiary Expands Data Centers
- Infrastructure Expansion Plans: Shuttle Pharmaceuticals' subsidiary United Dogecoin plans to expand data centers and power assets in Idaho and Alberta, aiming to support cryptocurrency mining and create capacity for commercial AI computing, signaling a strategic shift that led to a 44% stock price increase in after-hours trading.
- Triller Group's Space Investment: Triller Group announced the acquisition of an investment vehicle providing indirect exposure to SpaceX, resulting in a 296% surge during regular trading and an additional 30% in after-hours, reflecting strong investor enthusiasm for the company's high-value balance sheet strategy, with retail sentiment shifting from neutral to extremely bullish.
- INVO Fertility's Full Ownership: INVO Fertility completed the acquisition of its remaining joint-venture interest in an Alabama fertility clinic and resolved a Nasdaq compliance issue, leading to a 50% increase in after-hours trading, indicating heightened investor confidence in the reproductive healthcare sector, with retail sentiment improving from neutral to bullish.
- Strong Performance of Small Caps: Despite SHPH and IVF stocks declining 79% and 67% year-to-date, respectively, ILLR stock has surged 853%, demonstrating robust market interest in small-cap stocks and positive investor reactions to specific company developments.
See More
INVO Fertility Reports Q1 2026 Financial Results
- Reduced Financial Loss: INVO Fertility reported a net loss of $5.54 million for Q1 2026, significantly down from $17.40 million in 2025, primarily due to the discontinuation of NAYA therapeutics, which had contributed $15 million to last year's losses, thereby improving the company's financial outlook.
- Significant Improvement in Loss Per Share: The net loss per share for the quarter was $3.80, a dramatic improvement from $297.87 per share in the same period last year, indicating the company's efforts in cost control and operational optimization.
- Revenue Growth: The company achieved revenues of $2.01 million in the first quarter, representing a 23% increase from $1.64 million in the same quarter last year, reflecting positive performance amid recovering market demand and business expansion.
- Acquisition and Financing: INVO Fertility completed the acquisition of Family Beginnings in February 2026, adding a fourth fertility clinic in the U.S., while raising $7.1 million through warrant exercises, with $2 million allocated to settle deferred consideration related to the acquisition of Wisconsin Fertility Institute and to reduce debt.
See More
INVO Fertility Reports Q1 Earnings Decline Amid Revenue Growth
- Financial Overview: INVO Fertility reported a net loss of $5.539 million in Q1, an improvement from a loss of $17.403 million in the same period last year, indicating gradual financial health recovery.
- Revenue Growth: The company achieved revenue of $2.015 million in Q1, up 23.1% from $1.637 million last year, reflecting the positive impact of growth initiatives at the Georgia clinic and the acquisition of Family Beginnings.
- Drivers of Growth: The revenue increase is primarily driven by the growth strategies at the Georgia clinic and the integration of Family Beginnings, showcasing the company's strategic success in expanding services and market share.
- Future Outlook: Despite ongoing losses, the significant revenue growth provides INVO Fertility with potential for improved profitability in the future, particularly in the context of continued investment and market expansion.
See More
INVO Fertility Receives Nasdaq Delinquency Notice
- Nasdaq Delinquency Notice: INVO Fertility received a delinquency notice from Nasdaq on May 27, 2026, for failing to timely file its 10-K and 10-Q reports, although this notice currently does not affect the trading of its stock.
- Reasons for Filing Delay: The delay in filing the 10-K was attributed to the need for additional time to review complex accounting matters, including tax provisions and derivative accounting, which may impact investor perceptions of the company's financial health.
- Compliance Plan Deadline: Under Nasdaq rules, the company must submit a compliance plan by June 22, 2026; if accepted, it will have 180 days (until October 13, 2026) to regain compliance, which is critical for maintaining its listing status.
- Growth Strategy: The company completed a $7.5 million financing and acquired Family Beginnings, an Indiana-based fertility clinic, in January 2026, which strengthened its operations and balance sheet, with the upcoming 10-Q expected to reflect positive progress from these strategic initiatives.
See More
INVO Fertility Receives Nasdaq Compliance Notice for Late Filings
- Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing requirements due to late filings of financial reports, specifically the annual report for the year ended December 31, 2025, and the quarterly report for the quarter ended March 31, 2026.
- Impact of Delayed Reports: Despite the notice, INVO stated that it has no immediate effect on the listing or trading of its common stock on Nasdaq, reflecting the company's stability in the face of compliance issues.
- Remedial Actions: INVO filed its delayed annual report on June 2 and is working to complete and file the quarterly report as soon as possible, demonstrating the company's proactive approach to resolving compliance matters.
- Compliance Plan Timeline: Under Nasdaq rules, INVO must submit a compliance plan by June 22, 2026, and if accepted, Nasdaq may grant the company until October 13, 2026, to regain compliance, highlighting the urgency of the company's compliance efforts.
See More
INVO BioScience Reports Narrowed Losses in FY Earnings
- Financial Performance: INVO BioScience reported a FY GAAP EPS of -$214.64, with total revenue of $6.84 million, indicating ongoing financial challenges despite some revenue generation.
- Clinic Revenue Growth: Consolidated clinic revenue increased by 4% to $6,721,057 compared to $6,450,431 last year, suggesting a slight recovery in market demand.
- Net Loss Improvement: The net loss from continuing operations was $5.3 million, an improvement from $7.7 million in the previous year, indicating progress in cost control measures.
- Adjusted EBITDA: The adjusted EBITDA stood at -$3.2 million, worsening from -$2.2 million year-over-year, highlighting ongoing challenges in restoring profitability.
See More
Shuttle Pharmaceuticals Subsidiary Expands Data Centers
- Infrastructure Expansion Plans: Shuttle Pharmaceuticals' subsidiary United Dogecoin plans to expand data centers and power assets in Idaho and Alberta, aiming to support cryptocurrency mining and create capacity for commercial AI computing, signaling a strategic shift that led to a 44% stock price increase in after-hours trading.
- Triller Group's Space Investment: Triller Group announced the acquisition of an investment vehicle providing indirect exposure to SpaceX, resulting in a 296% surge during regular trading and an additional 30% in after-hours, reflecting strong investor enthusiasm for the company's high-value balance sheet strategy, with retail sentiment shifting from neutral to extremely bullish.
- INVO Fertility's Full Ownership: INVO Fertility completed the acquisition of its remaining joint-venture interest in an Alabama fertility clinic and resolved a Nasdaq compliance issue, leading to a 50% increase in after-hours trading, indicating heightened investor confidence in the reproductive healthcare sector, with retail sentiment improving from neutral to bullish.
- Strong Performance of Small Caps: Despite SHPH and IVF stocks declining 79% and 67% year-to-date, respectively, ILLR stock has surged 853%, demonstrating robust market interest in small-cap stocks and positive investor reactions to specific company developments.
See More
INVO Fertility Reports Q1 2026 Financial Results
- Reduced Financial Loss: INVO Fertility reported a net loss of $5.54 million for Q1 2026, significantly down from $17.40 million in 2025, primarily due to the discontinuation of NAYA therapeutics, which had contributed $15 million to last year's losses, thereby improving the company's financial outlook.
- Significant Improvement in Loss Per Share: The net loss per share for the quarter was $3.80, a dramatic improvement from $297.87 per share in the same period last year, indicating the company's efforts in cost control and operational optimization.
- Revenue Growth: The company achieved revenues of $2.01 million in the first quarter, representing a 23% increase from $1.64 million in the same quarter last year, reflecting positive performance amid recovering market demand and business expansion.
- Acquisition and Financing: INVO Fertility completed the acquisition of Family Beginnings in February 2026, adding a fourth fertility clinic in the U.S., while raising $7.1 million through warrant exercises, with $2 million allocated to settle deferred consideration related to the acquisition of Wisconsin Fertility Institute and to reduce debt.
See More
INVO Fertility Reports Q1 Earnings Decline Amid Revenue Growth
- Financial Overview: INVO Fertility reported a net loss of $5.539 million in Q1, an improvement from a loss of $17.403 million in the same period last year, indicating gradual financial health recovery.
- Revenue Growth: The company achieved revenue of $2.015 million in Q1, up 23.1% from $1.637 million last year, reflecting the positive impact of growth initiatives at the Georgia clinic and the acquisition of Family Beginnings.
- Drivers of Growth: The revenue increase is primarily driven by the growth strategies at the Georgia clinic and the integration of Family Beginnings, showcasing the company's strategic success in expanding services and market share.
- Future Outlook: Despite ongoing losses, the significant revenue growth provides INVO Fertility with potential for improved profitability in the future, particularly in the context of continued investment and market expansion.
See More
INVO Fertility Receives Nasdaq Delinquency Notice
- Nasdaq Delinquency Notice: INVO Fertility received a delinquency notice from Nasdaq on May 27, 2026, for failing to timely file its 10-K and 10-Q reports, although this notice currently does not affect the trading of its stock.
- Reasons for Filing Delay: The delay in filing the 10-K was attributed to the need for additional time to review complex accounting matters, including tax provisions and derivative accounting, which may impact investor perceptions of the company's financial health.
- Compliance Plan Deadline: Under Nasdaq rules, the company must submit a compliance plan by June 22, 2026; if accepted, it will have 180 days (until October 13, 2026) to regain compliance, which is critical for maintaining its listing status.
- Growth Strategy: The company completed a $7.5 million financing and acquired Family Beginnings, an Indiana-based fertility clinic, in January 2026, which strengthened its operations and balance sheet, with the upcoming 10-Q expected to reflect positive progress from these strategic initiatives.
See More
INVO Fertility Receives Nasdaq Compliance Notice for Late Filings
- Compliance Notice: INVO Fertility received a notice from Nasdaq indicating non-compliance with listing requirements due to late filings of financial reports, specifically the annual report for the year ended December 31, 2025, and the quarterly report for the quarter ended March 31, 2026.
- Impact of Delayed Reports: Despite the notice, INVO stated that it has no immediate effect on the listing or trading of its common stock on Nasdaq, reflecting the company's stability in the face of compliance issues.
- Remedial Actions: INVO filed its delayed annual report on June 2 and is working to complete and file the quarterly report as soon as possible, demonstrating the company's proactive approach to resolving compliance matters.
- Compliance Plan Timeline: Under Nasdaq rules, INVO must submit a compliance plan by June 22, 2026, and if accepted, Nasdaq may grant the company until October 13, 2026, to regain compliance, highlighting the urgency of the company's compliance efforts.
See More
INVO BioScience Reports Narrowed Losses in FY Earnings
- Financial Performance: INVO BioScience reported a FY GAAP EPS of -$214.64, with total revenue of $6.84 million, indicating ongoing financial challenges despite some revenue generation.
- Clinic Revenue Growth: Consolidated clinic revenue increased by 4% to $6,721,057 compared to $6,450,431 last year, suggesting a slight recovery in market demand.
- Net Loss Improvement: The net loss from continuing operations was $5.3 million, an improvement from $7.7 million in the previous year, indicating progress in cost control measures.
- Adjusted EBITDA: The adjusted EBITDA stood at -$3.2 million, worsening from -$2.2 million year-over-year, highlighting ongoing challenges in restoring profitability.
See More
